Molecular mechanism of PARP inhibitor resistance
Y Huang, S Chen, N Yao, S Lin, J Zhang, C Xu… - …, 2024 - pmc.ncbi.nlm.nih.gov
Poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi) are the first-approved anticancer
drug designed to exploit synthetic lethality. PARPi selectively kill cancer cells with …
drug designed to exploit synthetic lethality. PARPi selectively kill cancer cells with …
[HTML][HTML] In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach
Breast cancer remains one of the most prevalent and lethal malignancies in women,
particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately …
particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately …
A novel in silico approach for identifying multi-target JAK/STAT inhibitors as anticancer agents
Apoptosis, or programmed cell death, plays a pivotal role in maintaining cellular
homeostasis by eliminating damaged or surplus cells. Dysregulation of signaling pathways …
homeostasis by eliminating damaged or surplus cells. Dysregulation of signaling pathways …
A label-free electrochemical biosensor for sensitive analysis of the PARP-1 activity
H Yang, S Pu, P Shu, J Wang, YY Chen, X Yang… - …, 2025 - Elsevier
Early diagnosis of tumors is becoming increasingly important in modern healthcare. As
studies have demonstrated, Poly (ADP) ribose polymerase-1 (PARP-1) is overexpressed in …
studies have demonstrated, Poly (ADP) ribose polymerase-1 (PARP-1) is overexpressed in …
Building A Foundation Model for Drug Synergy Analysis Powered by Large Language Models
Drug synergy prediction is a challenging and important task in the treatment of complex
diseases including cancer. In this manuscript, we present a novel Foundation Model, known …
diseases including cancer. In this manuscript, we present a novel Foundation Model, known …
PARP inhibitors: beyond maintenance therapy
ZNY Phan - 2024 - search.proquest.com
Within the last decade, the development and approval of PARP inhibitors have
revolutionised the treatment landscape for many individuals living with cancer. These …
revolutionised the treatment landscape for many individuals living with cancer. These …